Infection

Ostro grows annual revenue by over 250%, closes Series B funding, celebrates co-founder

Retrieved on: 
Wednesday, January 4, 2023
Organization, Infection, Founders Fund, Patient, Health, Growth, HCPS, Marketing, MD, Multimedia, Cardiovascular disease, Therapy, Neurology, Pharmaceutical industry, Hunting, Ostro

MIAMI, Jan. 4, 2023 /PRNewswire/ -- Ostro, a leading healthcare engagement platform for consumers and HCPs, closed 2022 by celebrating a number of significant milestones: annual revenue growth of over 250%, Series B funding, a new website and brand identity, and a Forbes recognition for co-founder Ahmed Elsayyad.

Key Points: 
  • "I've never been more energized about the future of Ostro than I am right now," said Chase Feiger, MD, CEO of Ostro.
  • "I've never been more energized about the future of Ostro than I am right now," said Chase Feiger, MD, CEO of Ostro.
  • "For as long as I've known him, he's been laser-focused on selflessly delivering value to patients and HCPs.
  • In 2023, Ostro looks forward to building upon their success in 2022 and continuing to increase their client base, expand their product suite, and grow the Ostro team.

Global Legionella Testing Market 2023-2027

Retrieved on: 
Wednesday, January 4, 2023
SA, Intertek, Food safety, Tourist Railway Association, Inc., Quidel Corporation, Infection, SGS, United States national laboratories, Laboratory, TUV, UL, Research, UL LLC, Thermo Fisher Scientific, Retail

Our report on the legionella testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Key Points: 
  • Our report on the legionella testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.
  • The legionella testing market is segmented as below:
    This study identifies the emergence of new infectious diseases as one of the prime reasons driving the legionella testing market growth during the next few years.
  • Our report on the legionella testing market covers the following areas:
    This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading legionella testing market vendors that include AEMTEK Inc., Aerobiology Laboratory Associates Inc., Aquacert Ltd., Becton Dickinson and Co., bioMerieux SA, Eiken Chemical Co. Ltd., Element Materials Technology Group Ltd., EMSL Analytical Inc., Eurofins Scientific SE, IDEXX Laboratories Inc., Intertek Group Plc, Pace Analytical Services LLC, PDC Laboratories LLC, Pro Lab Diagnostics Inc., Quidel Corp., SGS SA, Thermo Fisher Scientific Inc., TUV NORD AG, UL LLC, and Bio Rad Laboratories Inc. Also, the legionella testing market analysis report includes information on upcoming trends and challenges that will influence market growth.

Helix & CDC to Study the Role of Human Genetics in Vaccine Effectiveness

Retrieved on: 
Wednesday, January 4, 2023
Severe acute respiratory syndrome coronavirus 2, BAA, Vaccination, Helix, COVID, Drug development, Biology, Partnership, CDC, Korea Disease Control and Prevention Agency, Public health, Health, Genomics, Infection, Multimedia, Government, Data, Broad Agency Announcement, Research, Genetics, Vaccine, Illumina

SAN MATEO, Calif., Jan. 4, 2023 /PRNewswire/ -- Helix, the leading population genomics and viral surveillance company in the nation, today announced a new Broad Agency Announcement (BAA) contract awarded by the Centers for Disease Control and Prevention (CDC) to better understand the role of human genetics in vaccine effectiveness particularly across SARS-CoV-2 variants. This new agreement extends the Company's viral sequencing leadership and further builds upon Helix's successful public-private partnership with the CDC.

Key Points: 
  • This new agreement extends the Company's viral sequencing leadership and further builds upon Helix's successful public-private partnership with the CDC.
  • "The new research conducted by Helix and CDC will uncover meaningful information to better understand and inform what we know of long COVID and other adverse effects.
  • The study will examine up to 10,000 individuals who have had breakthrough infections and severe COVID outcomes, despite being fully vaccinated.
  • Currently, few studies formally address the host genetics of vaccine effectiveness, or the interplay between host and viral genetic variation in the context of breakthrough infections.

Veterinary Vaccine Market Size to Reach USD 13,681.4 Million in 2030| Emergen Research

Retrieved on: 
Wednesday, January 4, 2023
Human, Veterinary medicine, Mortality, USD, Vaccination, Sustainable Development Goals, Lethargy, DVM, RNA, Municipal government in Canada, Student, Dog, University, United Nations Sustainable Development Group, Eli Lilly and Company, Zoonosis, Government, Growth, National Center for Biotechnology Information, CDC, Livestock, Risk, Food security, Disease, National Center for Immunization and Respiratory Diseases, Lead, DNA, Prevalence, Anaphylaxis, Society for the Prevention of Cruelty to Animals, Infection, Centers for Disease Control and Prevention, Clinical and Vaccine Immunology, Fever, Cat, Allergy, Vaccine, Merck & Co., Pet, Society, PETS, Animal, Elanco

VANCOUVER, B.C., Jan. 4, 2023 /PRNewswire/ -- The veterinary vaccine market size reached USD 7,975.3 Million in 2021 and is expected to register a CAGR of 6.2% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, B.C., Jan. 4, 2023 /PRNewswire/ -- The veterinary vaccine market size reached USD 7,975.3 Million in 2021 and is expected to register a CAGR of 6.2% during the forecast period, according to latest analysis by Emergen Research .
  • Increasing adoption of pets, rising prevalence of zoonotic diseases, and surging cases of COVID-19 are some key factors driving veterinary vaccine market revenue growth.
  • According to the report, it was stated that USD 59 million has been allocated to the provincial budget for 2022 to increase the Doctor of Veterinary Medicine (DVM) program.
  • The veterinary vaccine market is expected to register a CAGR of 6.2% over the forecast period and revenue is projected to increase from USD 7,975.3 Million in 2021 to USD 13,681.4 Million in 2030.

Veterinary Vaccine Market Size to Reach USD 13,681.4 Million in 2030| Emergen Research

Retrieved on: 
Wednesday, January 4, 2023
Human, Veterinary medicine, Mortality, USD, Vaccination, Sustainable Development Goals, Lethargy, DVM, RNA, Municipal government in Canada, Student, Dog, University, United Nations Sustainable Development Group, Eli Lilly and Company, Zoonosis, Government, Growth, National Center for Biotechnology Information, CDC, Livestock, Risk, Food security, Disease, National Center for Immunization and Respiratory Diseases, Lead, DNA, Prevalence, Anaphylaxis, Society for the Prevention of Cruelty to Animals, Infection, Centers for Disease Control and Prevention, Clinical and Vaccine Immunology, Fever, Cat, Allergy, Vaccine, Merck & Co., Pet, Society, PETS, Animal, Elanco

VANCOUVER, B.C., Jan. 4, 2023 /PRNewswire/ -- The veterinary vaccine market size reached USD 7,975.3 Million in 2021 and is expected to register a CAGR of 6.2% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, B.C., Jan. 4, 2023 /PRNewswire/ -- The veterinary vaccine market size reached USD 7,975.3 Million in 2021 and is expected to register a CAGR of 6.2% during the forecast period, according to latest analysis by Emergen Research .
  • Increasing adoption of pets, rising prevalence of zoonotic diseases, and surging cases of COVID-19 are some key factors driving veterinary vaccine market revenue growth.
  • According to the report, it was stated that USD 59 million has been allocated to the provincial budget for 2022 to increase the Doctor of Veterinary Medicine (DVM) program.
  • The veterinary vaccine market is expected to register a CAGR of 6.2% over the forecast period and revenue is projected to increase from USD 7,975.3 Million in 2021 to USD 13,681.4 Million in 2030.

Global Security Robots Market Report 2022 to 2028: Increasing Defense Budget is Expected to Escalate the Demand for Security Robots

Retrieved on: 
Wednesday, January 4, 2023
Human, Infection, Travel, Environment, Crime, HD, Robotics, Safety, Failure, Automation, Collection, Artificial intelligence, Temperature, University, Machine learning, Computer data storage

The Global Security Robots Market size is expected to reach $74.5 billion by 2028, rising at a market growth of 15.5% CAGR during the forecast period.

Key Points: 
  • The Global Security Robots Market size is expected to reach $74.5 billion by 2028, rising at a market growth of 15.5% CAGR during the forecast period.
  • Security robots are robotic devices that are created to carry out numerous duties, earlier done by humans.
  • These are autonomous guards that monitor and carry out security duties using streaming video, artificial intelligence (AI), and other linked technology.
  • The fact that these robots collect significantly more data than people suggests that they are more analogous to security mobile robots than typical security guards.

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

Retrieved on: 
Wednesday, January 4, 2023
Death, World Health Organization, CE, European Centre for Disease Prevention and Control, Environment, HPV, Growth, COVID-19, Diagnosis, Control, Risk, Nature, Cervical cancer, Union, Hepatitis B, Multimedia, Monkeypox, Therapy, Herpes simplex, Infection, Degenerative disease, Woman, Vaccine, Malaria, EU

LONDON, Jan. 4, 2023 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent. The specialized diagnostic kits can be found by contacting the Company's sales representatives.

Key Points: 
  • The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent.
  • These tests will cover more genotypes, have shorter processing times and lower costs than the currently available HPV tests in Europe.
  • Founded in 2013, Virax Biolabs is an Innovative Biotechnology company focused on the diagnosis of and the detection of immune responses to viral diseases.
  • T-Cell testing can be particularly effective in the management and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.

The Worldwide Hair Dryer Industry is Anticipated to Reach $13.6 Billion by 2030: Increasing Number of Professional Salons Drives Growth

Retrieved on: 
Wednesday, January 4, 2023
Online, Internet, Social media, International, Growth, COVID-19, Walmart, Hair, Dyson (company), Infection, Investment, Semiconductor, Beauty salon, Renewable energy, Consumer electronics, Online shopping, Amazon, Flipkart

Thus, the rising number of professional hair salons, particularly in emerging regions, is also anticipated to contribute to the hair dryer market growth in the forecast period.

Key Points: 
  • Thus, the rising number of professional hair salons, particularly in emerging regions, is also anticipated to contribute to the hair dryer market growth in the forecast period.
  • Moreover, increased investments in celebrity endorsement by cosmetics manufacturers to influence the target customers will drive the product demand.
  • Several hair dryer manufacturers reported a decline in sales due to the hampered supply of electric equipment and semiconductors.
  • Furthermore, the use of hair dryers for professional applications was reduced owing to social distancing norms imposed across the globe.

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma

Retrieved on: 
Wednesday, January 4, 2023
Human, MD Anderson Cancer Center, Hepatitis, ISA, Immunotherapy, Patient, HPV16, HLA, PRAME, Neoplasm, Epitope, Cell, CD8, Palestinian National Interest Committee, Immune system, Antigen, Preferential hyperacuity perimetry, Fund, Disease, University, B.V, Associate, Uveal melanoma, Breast, Central tolerance, Global Monitoring Plan, Safety, Clinical trial, Anderson, Pancreatic serous cystadenoma, Regeneron Pharmaceuticals, LSU, Infection, CD4, Principal, Cancer, Monroe Dunaway Anderson, Children's Art Project at The University of Texas MD Anderson Cancer Center, Investment, Lung, Research, Cancer/testis antigens, LP, Neuroblastoma, Pharmaceutical industry, Vaccine, Melanoma

OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/ -- ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA's PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.

Key Points: 
  • ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers.
  • We believe this investment from the Cancer Focus Fund and the clinical expertise provided by MD Anderson will significantly advance ISA103 as an immunotherapy with the potential to combat this rare but debilitating malignancy."
  • "Cancer Focus Fund is committed to using its investments to support the clinical development of truly innovative cancer therapies," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund.
  • The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center.

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma

Retrieved on: 
Wednesday, January 4, 2023
Human, MD Anderson Cancer Center, Hepatitis, ISA, Immunotherapy, Patient, HPV16, HLA, PRAME, Neoplasm, Epitope, Cell, CD8, Palestinian National Interest Committee, Immune system, Antigen, Preferential hyperacuity perimetry, Fund, Disease, University, B.V, Associate, Uveal melanoma, Breast, Central tolerance, Global Monitoring Plan, Safety, Clinical trial, Anderson, Pancreatic serous cystadenoma, Regeneron Pharmaceuticals, LSU, Infection, CD4, Principal, Cancer, Monroe Dunaway Anderson, Children's Art Project at The University of Texas MD Anderson Cancer Center, Investment, Lung, Research, Cancer/testis antigens, LP, Neuroblastoma, Pharmaceutical industry, Vaccine, Melanoma

OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/ -- ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA's PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.

Key Points: 
  • ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers.
  • We believe this investment from the Cancer Focus Fund and the clinical expertise provided by MD Anderson will significantly advance ISA103 as an immunotherapy with the potential to combat this rare but debilitating malignancy."
  • "Cancer Focus Fund is committed to using its investments to support the clinical development of truly innovative cancer therapies," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund.
  • The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center.